Fundamental research on effecitive whole-tumor-cell vaccine
| Project/Area Number |
18K07286
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
WADA Haruka 北海道大学, 遺伝子病制御研究所, 准教授 (70392181)
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2021: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | がん細胞ワクチン / ワクチン療法 / 腫瘍免疫 / がん免疫 |
|---|
| Outline of Final Research Achievements |
We have found that a sub-strain of 4T1 (4T1-S), which was discovered by chance, produces a remarkable vaccine effect after X-irradiation. We investigated whether the vaccine response factors could be selected by comparable analysis of gene expression between 4T1-S and its parent strain, 4T1-A, and whether the ineffective vaccine could be converted to an effective vaccine. We found 15 factors that were highly expressed after X-irradiation in the vaccine effective strain. The top three genes were transfected into 4T1-A and the vaccine effect was analyzed, and the effect was enhanced. On the other hand, when the top 3 genes were introduced into CT26 cells with weak vaccine effect and vaccine experiments were performed, complete vaccine effect was observed in all individuals. Therefore, it is clear that the introduction of only the top three genes is effective for the the vaccine effect in some cancer types and individuals.
|
| Academic Significance and Societal Importance of the Research Achievements |
がん細胞ワクチンは抗原同定の必要がなく、理論上はすべての患者に有効な可能性のあるワクチンであるため期待は非常に大きかった。しかしがん細胞ワクチンは有効性に乏しく、現在では着目されることはほとんどなくなっている。この状況下、我々はワクチン有効である4T1-S、4T1-Aの発見と解析により、無効ワクチン細胞を有効化する因子を同定した点で学術的意義がある。同定した因子を元に全がん細胞ワクチンを開発できれば、再発予防療法の選択肢が広がることとなる。従ってがん患者にとって福音となり、社会的にも意義がある。
|
Report
(5 results)
Research Products
(20 results)
-
-
-
-
[Journal Article] Flow cytometric identification and cell-line establishment of macrophages in naked mole-rats.2019
Author(s)
Haruka Wada, Yuhei Shibata, Yurika Abe, Ryo Otsuka, Nanami Eguchi, Yoshimi Kawamura, Kaori Oka, Muhammad Baghdadi, Tatsuya Atsumi, Kyoko Miura, and Ken-ichiro Seino.
-
Journal Title
Scientific Reports
Volume: 9
Pages: 17981-17981
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Prognostic value of IL-34 in colorectal cancer patients2019
Author(s)
Takuto Kobayashi, Muhammad Baghdadi, Nanumi Han, Tomoki Murata, Naoki Hama, Ryo Otsuka, Haruka Wada, Manabu Shiozawa, Tomoyuki Yokose, Yohei Miyagi, Atsushi Takano, Yataro Daigo, Ken-ichiro Seino.
-
Journal Title
Immunological Medicine
Volume: 42
Pages: 169-175
Related Report
Peer Reviewed
-
[Journal Article] Interleukin-34 expression in ovarian cancer: A possible correlation with disease progression.2019
Author(s)
Hiraku Endo, Naoki Hama, Muhammad Baghdad, Kozo Ishikawa, Ryo Otsuka Haruka Wada, Hiroshi Asano, Daisuke Endo, Yosuke Konno, Tatsuya Kato, Hidemichi Watari, Akiko Tozawa, Nao Suzuki, Tomoyuki Yokose, Atsushi Takano, Hisamori Kato, Yohei Miyagi, Yataro Daigo, Ken-ichiro Seino.
-
Journal Title
International Immunology
Volume: 32
Issue: 3
Pages: 175-186
DOI
NAID
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-
-
